Exjade 250 mg, dispergierbare Tabletten - 84 Tablette(n) Swissmedic Key 57466007 Registration Holder Novartis Pharma Schweiz AG Name Exjade 250 mg, dispergierbare Tabletten Date of registration 03.11.2005 Introduction of Sequence 03.11.2005 ATC-Classification Deferasirox (V03AC03) Revision date 19.10.2007 WHO WHO-DDD Valid until Index Therapeuticus (BSV) 06.99. Show package size 84 Tablette(n) Index Therapeuticus (Swissmedic) 06.99. Description Swissmedic categorie. B SL Eintrag No Indication Information for professionals IP Consumer information CI Ex-factory-Price 1632.58 Deductible k.A. Consumer price 1852.05 Feedback FB GTIN 7680574660072 Medication Code Synthetika Pharmacode Disponibility
Composition deferasiroxum 250 mg, crospovidonum, lactosum monohydricum 271.8 mg, cellulosum microcristallinum, povidonum K 30, natrii laurilsulfas, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 0.340 mg. Packungsbestandteile Galenic Form Dispersible Tablets Active Agent Dose Deferasirox 250 mg
Inactive agents Dose Cellulosum Microcristallinum Crospovidonum Lactose Monohydrate 271.8 mg Magnesii Stearas Natrii Laurilsulfas Povidonum K 30 Pro Compresso Silica Colloidalis Anhydrica
Source Data was imported : 05.08.2020
Swissmedic Registration :
Sequence :
Product name :
Registration owner: :
Product group :
Index Therapeuticus (BSV) :
Medication Code :
Date of registration :
Valid until :
Package number :
Show package size :
Commercial Form/Unit :
Swissmedic categorie. :
Active Agents :
Composition :
